Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis
Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trialsClimacteric. 2018 Apr;21(2):189-195
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Six randomized controlled trials were included in this meta-analysis which compared the effects of romosozumab to placebo, teriparatide, and alendronate in postmenopausal osteoporosis treatment. The change in bone mineral density at the lumbar spine, total hip, and femoral neck significantly favoured romosozumab versus both placebo and active controls. Fracture rates after 24 months also significa...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE